Skip to main content
. 2020 Mar;8(5):202. doi: 10.21037/atm.2020.01.56

Table 4. Incidence of acute respiratory failure for the study cohort stratified by comorbidities and estimation of the risk of respiratory failure for different levels of comorbidities using multivariate Cox proportional hazards regression analysis.

Variable Non-PM/DM cohort PM/DM cohort Adjusted HR (95% CI) P value*
Event PYs Rate Event PYs Rate
Asthma 0.0934
   No 281 85,319 32.9 141 6,679 211.1 5.62 (4.43–7.12)
   Yes 54 5,017 107.6 30 774 387.6 3.58 (2.13–6.01)
Hypertension 0.0008
   No 107 67,873 15.8 97 5,723 169.5 7.90 (5.56–11.20)
   Yes 228 22,463 101.5 74 1,730 427.7 4.01 (2.99–5.36)
Diabetes 0.06
   No 237 82,453 28.7 140 6,786 206.3 5.83 (4.56–7.45)
   Yes 98 7,883 124.3 31 667 464.8 3.69 (2.34–5.83)
COPD 0.005
   No 242 84,163 28.8 129 6,508 198.2 6.21 (4.82–8.01)
   Yes 93 6,173 150.7 42 945 444.4 3.04 (2.04–4.54)
Pneumonia 0.4808
   No 254 78,790 32.2 102 5,690 179.3 4.60 (3.53–6.00)
   Yes 81 11,546 70.2 69 1,763 391.4 6.08 (4.22–8.78)
Cancer 0.5946
   No 311 88,625 35.1 162 7,211 224.7 5.75 (4.64–7.13)
   Yes 24 1,711 140.3 9 241.5 372.7 3.46 (1.44–8.34)
CAD 0.2117
   No 211 79,628 26.5 123 6,471 190.1 5.09 (3.89–6.65)
   Yes 124 10,708 115.8 48 982 488.8 4.94 (3.40–7.16)
Heart failure 0.06
   No 305 89,092 34.2 160 7,236 221.1 5.95 (4.79–7.39)
   Yes 30 1,244 241.2 11 217 506.9 2.64 (1.19–5.85)
PVD 0.0388
   No 326 90,114 36.2 165 7,361 224.2 5.38 (4.33–6.68)
   Yes 9 221 407.2 6 91 659.3 18.4 (2.21–153.80)

Adjusted for age, sex, CCI score, and medicine of oral steroid. *, P for interaction. PM/DM, polymyositis/dermatomyositis; rate, per 10,000 person-years; PYs, person-years; CI, confidence interval; HR, hazard ratio; COPD, chronic obstructive pulmonary disease; CAD, coronary artery disease; PVD, pulmonary vascular disease; CCI score, Charlson comorbidity index score.